Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 268,022	$ 241,452
Restricted cash	20,000	20,000
Accounts receivable	18,976	19,748
Prepaid & other current assets	58,546	21,964
Total current assets	365,544	303,164
In process R&D	1,101,760	1,101,760
Goodwill, net of impairment	5,988,230	12,071,376
Investment in GMP Bio at fair value	22,640,519	22,640,519
Total assets	30,096,053	36,116,819
Current liabilities:
Accounts payable and accrued liabilities	2,439,812	2,510,864
Contingent consideration	2,625,000	2,625,000
Derivative liability on notes	218,898	198,140
Total current liabilities	17,111,408	16,923,407
Convertible long-term debt, net of costs	899,099
Commitments and contingencies (Note 12)
Stockholders’ equity:
Common stock, $.01 par value; 750,000,000 shares authorized; 398,159,128 and 391,846,880 issued and outstanding, respectively	3,981,589	3,918,469
Additional paid-in capital	41,348,213	41,416,632
Accumulated deficit	(32,780,753)	(25,926,069)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	12,549,049	19,409,032
Non-controlling interests	(463,503)	(215,620)
Total stockholders’ equity	12,085,546	19,193,412
Total liabilities and stockholders’ equity	30,096,053	36,116,819
Related Party [Member]
Current liabilities:
Accounts payable - related party	343,673	332,432
Convertible debt and short-term debt - related party, net of costs	1,832,410	1,165,048
Nonrelated Party [Member]
Current liabilities:
Convertible debt and short-term debt - related party, net of costs	$ 9,651,615	$ 10,091,923